PT  - JOURNAL ARTICLE
AU  - Kontogianni, Konstantina
AU  - Bengey, Daisy
AU  - Wooding, Dominic
AU  - Buist, Kate
AU  - Greenland-Bews, Caitlin
AU  - Williams, Christopher T.
AU  - de Vos, Margaretha
AU  - Escadafal, Camille
AU  - Adams, Emily R.
AU  - Edwards, Thomas
AU  - Cubas-Atienzar, Ana I.
TI  - Analytical evaluation of thirty-two SARS-CoV-2 lateral flow antigen tests demonstrates sensitivity remains with the SARS-CoV-2 Gamma lineage
AID  - 10.1101/2021.12.08.21267455
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.08.21267455
4099  - http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267455.short
4100  - http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267455.full
AB  - The limit of detection (LOD) of thirty-two antigen lateral flow tests (Ag-RDT) were evaluated with the SARS-CoV-2 Gamma variant. Twenty-eight of thirty-two Ag-RDTs exceeded the World Health Organization criteria of an LOD of 1.0×106 genome copy numbers/ml and performance was equivalent as with the 2020 B.1 lineage and Alpha variant.Competing Interest StatementE.R. Adams is an employee of Mologic. M. de Vos and C. Escadafal are employees of FIND. E.R. Adams and FIND had no role in data collection and analysis.Funding StatementThe study was supported by the global alliance for diagnostics (FIND).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request